COL6A2 and central nervous system cancer: The tissue microarray (TMA) prognostic analysis corroborated the TCGA, CGGA and GEO databases, high expression was unfavorable to survival in glioma patients, and 5-year overall survival was significantly shorter in glioma patients with high COL6A2 expression levels compared with counterparts with low COL6A2 expression levels (p=0.025, Figure 3D).